11 recruiting, 8 active not recruiting, 8 completed, 5 terminated. 26 Phase 2, 17 Phase 1, 3 Phase 3, 1 Not applicable.
Follow Metastatic Uveal Melanoma: new trials by email Literature Review of Metastatic Uveal Melanoma trials Research Report on Metastatic Uveal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide - Unresectable Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-04 |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2025-12-31 | 2026-03-31 |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. - Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic | Phase 1 / Phase 2 | Recruiting | Novelwise Pharmaceutical Corporation | 36 | 2025-11-20 | 2025-11-28 |
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| Adding IL-2 to Tebentafusp to Eradicate Cancer Progression Aldesleukin - Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | St Vincent's Hospital, Sydney | 8 | 2025-06-01 | 2025-07-14 |
| Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | Phase 2 | Recruiting | University of Miami | 30 | 2025-02-14 | 2026-02-23 |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Completed | Vastra Gotaland Region | 8 | 2023-02-06 | 2025-09-22 |
| Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma BRD4 Inhibitor PLX2853, Trametinib, Computed Tomography - Advanced Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Withdrawn | Alliance for Clinical Trials in Oncology | 2023-01-13 | 2023-08-18 | |
| A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma Lifileucel (LN-144/LN-145) - Uveal Melanoma, Melanoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2022-11-01 | 2026-09-15 |
| Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Pembrolizumab 25 MG/1 ML Intravenous Solution - Metastatic Uveal Melanoma | Phase 2 | Completed | Institut Curie | 51 | 2022-07-07 | 2026-07-28 |
| A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas DYP688 - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 66 | 2022-07-04 | 2026-07-28 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) - Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 3 | Active not recruiting | Delcath Systems Inc. | 30 | 2022-06-10 | 2023-12-21 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Binimetinib, Belinostat - Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2021-12-15 | 2026-04-06 |
| Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel - Metastatic Esophageal, Gastric Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 352 | 2021-11-12 | 2026-06-12 |
| Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Carmustine, Ethiodized Oil, Transarterial Chemoembolization - Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | Thomas Jefferson University | 28 | 2021-09-27 | 2026-05-06 |
Showing 20 of 37. Sign in to see all of them.
Uveal Melanoma (37) · Melanoma (15) · Neoplasm Metastasis (7) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Eye Neoplasms (3) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Meningeal Neoplasms (1) · Nevus (1)
Eye Diseases (37) · Neoplasms by Histologic Type (37) · Neoplasms by Site (37) · Neoplasms, Germ Cell and Embryonal (37) · Neoplasms, Nerve Tissue (37) · Neuroectodermal Tumors (37) · Neuroendocrine Tumors (37) · Nevi and Melanomas (37) · Uveal Diseases (37) · Uveal Neoplasms (37) · Eye Neoplasms (34) · Neoplasms (34) · Melanoma (22) · Skin Diseases (16) · Skin and Connective Tissue Diseases (16)
Nivolumab (7) · Ipilimumab (5) · Cyclophosphamide (4) · CTLA-4 Antigen (3) · Interleukin-2 (3) · Melphalan (3) · aldesleukin (3) · pembrolizumab (3) · Carmustine (2) · Crizotinib (2) · Dacarbazine (2) · Magnetic Resonance Spectroscopy (2) · binimetinib (2) · fludarabine (2) · fludarabine phosphate (2)
M.D. Anderson Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Thomas Jefferson University (3) · Vastra Gotaland Region (3) · IDEAYA Biosciences (2) · Institut Curie (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Beijing Biotech (1) · Delcath Systems Inc. (1) · Eric Bernicker, MD (1) · Foghorn Therapeutics Inc. (1) · GlaxoSmithKline (1) · Jose Lutzky, MD (1) · Mayo Clinic (1)
United States (27) · Australia (5) · France (5) · Netherlands (3) · United Kingdom (3) · Canada (2) · Germany (2) · Spain (2) · Sweden (2) · Switzerland (2) · Belgium (1) · China (1) · Israel (1) · Italy (1) · Poland (1)
Rino Seedor, MD (2) · Ahmad Tarhini, MD, PHD (1) · Ahmad Tarhini, MD, PhD (1) · Alexander N Shoushtari (1) · Anthony Joshua, FRACP (1) · Carin Gonsalves, MD (1) · Eric Bernicker, M.D. (1) · Eric Wachter, PhD (1) · Ernest Marshall (1) · George Cole Jr., MD (1) · Hetal Patel, MD, MSHS, CHCQM (1) · Isabella C Glitza, MD (1) · Jay Wu, PhD (1)
PMID 16344433, PMID 28395880, PMID 31046743, PMID 33125309, PMID 33827976, PMID 34453044, PMID 34663687, PMID 35019850, PMID 36997799, PMID 37377898, PMID 39198868, PMID 41850738, PMID 42443515, PMID 9437317
2008 (1), N01CM00100 (1), N01CM62206 (1), P30CA008748 (1), R21CA208609 (1), U01CA069856 (1), UM1CA186689 (1)